Latest Videos |view all videos
A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease.
Dr. David Dingli, a Professor of Medicine and member of the division of Hematology at Mayo Clinic in Rochester, MN, updates clinicians and patients on new treatment options for this increasingly complicated disease progression.
This Breast Center Grand Rounds introduces the evidence of acupuncture's effectiveness in managing key symptoms of cancer treatment.
Mayo Clinic physicians John B. Kisiel, M.D. and David W. Larson, M.D. discuss the latest advancements in colorectal cancer screening, as well as the latest surgical techniques available for patients with colorectal cancer.
Mayo Clinic’s multidisciplinary team of experts discuss hematologic malignancies and the latest developments in the treatment of these cancers.
Medical oncologists, Scott H. Okuno, M.D. and Steven I .Robinson, M.B.B.S., and orthopedic surgeon, Peter S. Rose, M.D. discuss sarcomas—a group of rare soft tissue and bone cancers—and the unique treatment options for these cancers.
Mayo Clinic’s medical oncologists and urologists discuss their multidisciplinary approach to the treatment of various genitourinary cancers.
Mayo Clinic experts in Arizona discuss the new facility which allows them to create a seamless experience for patients by integrating all cancer services from prevention to survivorship.
Mayo Clinic’s multidisciplinary team of experts discuss developments in diagnostic tools, imaging, neurosurgery, and radiation therapy that allow them to create personalized care plans for patients with brain and central nervous system cancers.
Mayo Clinic physicians and researchers discuss how the molecular makeup of brain tumors can be used to identify five categories of gliomas, each with different clinical features and outcomes.
In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic’s Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
The genetic makeup of colon cancer tumors and survival rates for patients with the disease differ by race, according to a study from researchers at the Mayo Clinic Cancer Center.
Grand Rounds Cancer Videos